 Onconova Therapeutics, Inc. ONTX, a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes MDS, today announced the e-publication of results from a Phase 1 company-sponsored study of oral rigosertib in combination with standard dose azacitidine in the treatment of patients diagnosed with either higher-risk myelodysplastic syndrome HR-MDS or acute myeloid leukemia AML in the international hematological malignancy journal Leukemia Research. The results from this Phase 1 study represent Onconovas first efforts to explore oral rigosertib in combination with azacitidine to address the unmet medical need in patients with MDS and AML. 